Filing Details

Accession Number:
0001104659-24-130963
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-12-20 21:30:54
Reporting Period:
2024-12-18
Accepted Time:
2024-12-20 21:30:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651407 Checkpoint Therapeutics Inc. CKPT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1434718 Iii F James Oliviero 95 Sawyer Rd, Suite 110
Waltham MA 02453
Ceo, President And Director Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-12-18 602,167 $3.87 3,414,813 No 4 S Direct
Common Stock Disposition 2024-12-19 220,230 $3.38 3,194,583 No 4 S Direct
Common Stock Disposition 2024-12-20 900,000 $0.00 2,294,583 No 4 G Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 G Direct
Footnotes
  1. In connection with the vesting of 2,111,033 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock.
  2. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.66 to $4.27. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Includes shares of restricted common stock, which vest over various time periods.
  4. Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.33 to $3.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
  5. On December 20, 2024, 900,000 shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Oliviero's minor children. Mr. Oliviero is not a trustee of the trust and has no investment control over the securities held by the trust.